Syros Pharmaceuticals (SYRS)
OTHER OTC:SYRS
Top Page
No summary available
Positive Factors
Market Opportunity
The significant market potential for tamibarotene provides a substantial growth opportunity, positioning Syros to capture a large share of the higher-risk MDS therapeutics market.
Negative Factors
Financial Instability
The negative equity position indicates financial instability, posing risks to Syros' ability to fund operations and invest in growth initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Market Opportunity
The significant market potential for tamibarotene provides a substantial growth opportunity, positioning Syros to capture a large share of the higher-risk MDS therapeutics market.
Read all positive factors
Syros Pharmaceuticals (SYRS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.37K
Dividend YieldN/A
Average Volume (3M)98.49K
Price to Earnings (P/E)―
Beta (1Y)10.64
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees68
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding26,832,457
10 Day Avg. Volume38,912
30 Day Avg. Volume98,487
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)13.24
Price to Sales (P/S)22.21
P/FCF Ratio-2.01
Enterprise Value/Market Cap-14.43K
Enterprise Value/Revenue-200.64
Enterprise Value/Gross Profit87.71
Enterprise Value/Ebitda0.85
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Syros Pharmaceuticals Business Overview & Revenue Model
Company Description
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a sele...
How the Company Makes Money
Syros Pharmaceuticals generates revenue primarily through collaborations and strategic alliances with other pharmaceutical companies, which may include upfront payments, milestone payments, and royalties based on product sales. The company may als...
Syros Pharmaceuticals Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 386.00K | 9.94M | 14.88M | 23.49M | 15.09M | 1.98M |
| Gross Profit | -883.00K | 7.68M | 11.91M | 23.49M | 15.09M | 1.98M |
| EBITDA | -91.22M | -157.19M | -87.55M | -79.63M | -79.21M | -72.72M |
| Net Income | -97.81M | -164.57M | -94.65M | -86.56M | -84.04M | -75.44M |
Balance Sheet | ||||||
| Total Assets | 85.00M | 168.17M | 244.49M | 182.94M | 213.25M | 149.98M |
| Cash, Cash Equivalents and Short-Term Investments | 58.27M | 139.53M | 202.30M | 130.37M | 173.98M | 91.42M |
| Total Debt | 60.23M | 62.08M | 63.57M | 65.19M | 66.21M | 25.92M |
| Total Liabilities | 96.12M | 151.51M | 116.75M | 97.72M | 122.70M | 70.79M |
| Stockholders Equity | -11.12M | 16.66M | 127.74M | 85.22M | 90.55M | 79.18M |
Cash Flow | ||||||
| Free Cash Flow | -100.06M | -109.98M | -124.31M | -100.78M | -60.70M | -72.89M |
| Operating Cash Flow | -100.02M | -109.71M | -123.06M | -99.54M | -57.36M | -60.25M |
| Investing Cash Flow | 1.95M | 37.34M | 67.19M | -52.65M | 46.66M | -11.73M |
| Financing Cash Flow | 43.16M | 43.46M | 131.04M | 70.51M | 142.95M | 65.99M |
Syros Pharmaceuticals Technical Analysis
Neutral
0.02
Price Trends
0.02
Negative
0.04
Negative
0.42
Negative
Market Momentum
>-0.01
Negative
51.08
Neutral
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SYRS, the sentiment is Neutral. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.42, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 51.08 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SYRS.
Syros Pharmaceuticals Risk Analysis
Syros Pharmaceuticals disclosed 73 risk factors in its most recent earnings report. Syros Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Syros Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $5.37K | ― | -776.96% | ― | ― | ― | |
49 Neutral | $2.12M | -0.24 | ― | ― | 178.82% | -4121.10% | |
42 Neutral | $1.75M | -0.07 | -63.03% | ― | -100.00% | 86.75% | |
| ― | $2.54M | -0.17 | -168.95% | ― | ― | 90.27% |
* Healthcare Sector Average
SYRS
Syros Pharmaceuticals
0.02
>-0.01
-33.33%
BDRX
Biodexa Pharmaceuticals
0.87
-15.63
-94.71%
QCLS
Q/C Technologies
3.51
-33.01
-90.39%
SCNI
Scinai Immunotherapeutics
0.61
-2.05
-77.07%
OGEN
Oragenics
0.58
-4.64
-88.81%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―